Key Retreatment Decisions in the Clinical Trials for Faricimab in nAMD

Novartis acquired Gyroscope Holdings Limited from Syncona in February 2022

According to the company, it is working with the FDA to address the agency’s issues.

The geographic atrophy treatment was approved by the FDA in the US earlier this month.

The study met its primary efficacy endpoint for the neovascular age-related macular degeneration (nAMD) treatment.

IZERVAY is expected to be available in the United States within 2 to 4 weeks.

In the study, researchers found that nearly one-quarter of anti-VEGF injections were received at least 1 week later than intended.